HUE049806T2 - Módosított gazdasejtek és alkalmazásaik - Google Patents

Módosított gazdasejtek és alkalmazásaik

Info

Publication number
HUE049806T2
HUE049806T2 HUE14784210A HUE14784210A HUE049806T2 HU E049806 T2 HUE049806 T2 HU E049806T2 HU E14784210 A HUE14784210 A HU E14784210A HU E14784210 A HUE14784210 A HU E14784210A HU E049806 T2 HUE049806 T2 HU E049806T2
Authority
HU
Hungary
Prior art keywords
host cells
modified host
modified
cells
host
Prior art date
Application number
HUE14784210A
Other languages
English (en)
Inventor
Michael Kowarik
Stefan J Kemmler
Julien L Quebatte
Christiane Marie-Paule Simone Jeanne Feron
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE049806T2 publication Critical patent/HUE049806T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HUE14784210A 2014-04-17 2014-10-13 Módosított gazdasejtek és alkalmazásaik HUE049806T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461980988P 2014-04-17 2014-04-17

Publications (1)

Publication Number Publication Date
HUE049806T2 true HUE049806T2 (hu) 2020-10-28

Family

ID=51726491

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14784210A HUE049806T2 (hu) 2014-04-17 2014-10-13 Módosított gazdasejtek és alkalmazásaik

Country Status (17)

Country Link
US (1) US20170035900A1 (hu)
EP (2) EP3711776B1 (hu)
JP (2) JP6682451B2 (hu)
CN (1) CN106794237B (hu)
BR (1) BR112016023688B1 (hu)
CA (1) CA2945542C (hu)
CY (1) CY1123403T1 (hu)
DK (1) DK3131577T3 (hu)
ES (2) ES2805000T3 (hu)
HR (1) HRP20201021T1 (hu)
HU (1) HUE049806T2 (hu)
LT (1) LT3131577T (hu)
MX (1) MX2016013631A (hu)
PL (1) PL3131577T3 (hu)
PT (1) PT3131577T (hu)
SI (1) SI3131577T1 (hu)
WO (1) WO2015158403A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CN105732818B (zh) * 2016-03-02 2019-06-07 中国人民解放军第三军医大学 一种铜绿假单胞菌重组蛋白pop及其制备方法和应用
CA3067587A1 (en) * 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation Immunogenic compositions
US11993778B2 (en) 2017-10-25 2024-05-28 Pivot Bio, Inc. Methods and compositions for improving engineered microbes that fix nitrogen
CN112584699A (zh) * 2018-06-27 2021-03-30 皮沃特生物股份有限公司 引导微生物重塑、农业微生物物种合理改良的平台
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
JP2022525773A (ja) 2019-03-18 2022-05-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 大腸菌o抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法
WO2021180532A1 (en) * 2020-03-12 2021-09-16 Malcisbo Ag Vaccines comprising glycoengineered bacteria
EP4213870A1 (en) 2020-09-17 2023-07-26 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE317897T1 (de) 2002-03-07 2006-03-15 Eidgenoess Tech Hochschule System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
PL2311972T3 (pl) * 2005-05-11 2015-08-31 Eth Zuerich Rekombinowane n-glikozylowane białka z komórek prokariotycznych
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
PL2257307T3 (pl) * 2008-02-20 2018-11-30 Glaxosmithkline Biologicals S.A. Biokoniugaty wytworzone z rekombinowanych n-glikozylowanych białek z komórek prokariotycznych
EP2501406B8 (en) 2009-11-19 2018-01-24 GlaxoSmithKline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
CN103079591B (zh) * 2010-05-06 2017-07-28 格林考瓦因有限公司 荚膜革兰氏阳性细菌生物缀合物疫苗
EP2753353A1 (en) * 2011-09-06 2014-07-16 Glycovaxyn AG Bioconjugate vaccines made in prokaryotic cells
WO2014037585A1 (en) * 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
JP6329554B2 (ja) * 2012-10-12 2018-05-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 宿主細胞改変方法
EP3508579B1 (en) * 2012-11-07 2021-06-30 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
EP3055416B1 (en) * 2013-10-11 2020-01-22 GlaxoSmithKline Biologicals S.A. Methods of host cell modification

Also Published As

Publication number Publication date
ES2805000T3 (es) 2021-02-10
CN106794237A (zh) 2017-05-31
EP3711776B1 (en) 2023-01-11
ES2939470T3 (es) 2023-04-24
WO2015158403A1 (en) 2015-10-22
BR112016023688B1 (pt) 2024-01-09
HRP20201021T1 (hr) 2020-10-16
CA2945542C (en) 2024-03-05
EP3131577A1 (en) 2017-02-22
CN106794237B (zh) 2022-04-12
DK3131577T3 (da) 2020-07-13
US20170035900A1 (en) 2017-02-09
BR112016023688A2 (pt) 2018-01-30
JP6682451B2 (ja) 2020-04-15
EP3131577B1 (en) 2020-04-22
JP2020114232A (ja) 2020-07-30
PT3131577T (pt) 2020-07-17
CA2945542A1 (en) 2015-10-22
MX2016013631A (es) 2017-02-28
EP3711776A1 (en) 2020-09-23
LT3131577T (lt) 2020-07-27
CY1123403T1 (el) 2022-03-24
SI3131577T1 (sl) 2020-08-31
JP2017513480A (ja) 2017-06-01
PL3131577T3 (pl) 2020-10-19

Similar Documents

Publication Publication Date Title
HK1243332A1 (zh) 改變在修飾的t細胞中的基因表達及其用途
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
IL247344A0 (en) A new polysaccharide and its uses
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL246755A0 (en) The heteroaryls and their use
SG11201609118RA (en) Modified natural killer cells and uses thereof
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
HK1231555A1 (zh) 生物標誌物及其用途
PL3131577T3 (pl) Zmodyfikowane komórki gospodarze i ich zastosowanie
SG11201704473WA (en) New methods and uses
SG11201610514SA (en) Bioreactor and uses thereof
GB201408091D0 (en) Methods and uses
GB201622225D0 (en) Modified host cells and uses thereof
GB201419897D0 (en) Host cell
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
EP3233107A4 (en) Nbp158 and uses thereof
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses
AU2014901389A0 (en) Immune cell markers and uses thereof
AU2014901388A0 (en) Immune cell markers and uses thereof
AU2014901390A0 (en) Immune cell markers and uses thereof
AU2014904616A0 (en) Biomarkers and uses thereof
GB201415379D0 (en) Gamma T cells and uses thereof
GB201407419D0 (en) Conductive materials and uses thereof
GB201412175D0 (en) Gamma T cells and uses thereof